Alternative ValueThe company's alternative value business generated significant profit and is projected to grow double digits, suggesting a potential re-rate of the stock.
Financial FlexibilityThe sale of non-core specialty pharmacy business should be modestly value accretive, enhancing the company's financial flexibility.
Stock BuybackPotential for a huge buyback is growing, indicating a bullish sentiment for the stock.